GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
E

Eagle Pharmaceuticals EGRX · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.82

-8.89%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2022

Revenue

$316.6m

FY2014FY2022

Net income

$35.6m

FY2014FY2022

Free cash flow

$50.5m

FY2014FY2022

Shareholders' equity

$233.6m

FY2014FY2022

Income statement

Fiscal years

FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Revenue$316.6m$171.5m$187.8m$195.9m$213.3m$236.7m$189.5m$66.2m$19.1m
Gross profit$221.7m$129.4m$142.3m$135.0m$151.4m$179.5m$134.2m$50.6m$7.4m
Research and development$34.1m$51.3m$30.8m$36.8m$44.4m$32.6m$30.3m$27.9m$16.8m
Operating income$81.0m$2.8m$33.0m$21.8m$36.6m$74.0m$53.4m$2.6m−$18.8m
Net income$35.6m−$8.6m$12.0m$14.3m$31.9m$51.9m$81.5m$2.6m−$18.0m
Diluted earnings per share2.72-0.670.871.012.173.345.000.15-1.28

Balance sheet

At each fiscal year end

FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Total assets$406.2m$253.7m$253.2m$254.6m$238.6m$270.1m$213.6m$124.6m$53.4m
Cash and short-term investments$55.3m$97.7m$103.2m$109.8m$78.8m$114.7m$52.8m$79.1m$42.7m
Total liabilities$172.6m$77.3m$67.2m$75.4m$77.8m$90.9m$62.3m$34.3m$20.3m
Debt$67.8m$29.8m$38.2m$38.6m$44.4m$47.8m—$86,000$9.2m
Shareholders' equity$233.6m$176.5m$186.0m$179.2m$160.8m$179.1m$151.2m$90.3m$33.1m
Shares outstanding13m13m14m14m15m16m16m17m14m

Cash flow

Fiscal years

FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Cash from operations$50.7m$28.2m$49.5m$56.0m$52.4m$58.9m$53.2m−$9.7m−$13.8m
Capital spending−$178,000−$323,000−$747,000−$777,000−$133,000−$5.2m−$20.7m−$1.9m−$46,000
Free cash flow$50.5m$27.9m$48.8m$55.2m$52.3m$53.7m$32.5m−$11.6m−$13.9m
Dividends paid−$1.7m−$2.4m−$3.7m−$260,000—————

Latest quarters

By quarter end

Jun 2023Mar 2023Dec 2022Sept 2022Jun 2022Mar 2022Dec 2021Sept 2021
Revenue$64.6m$66.3m$60.7m$65.9m$74.1m$115.9m$42.3m$39.9m
Gross profit$47.8m$49.0m$40.8m$42.3m$50.5m$88.1m$30.0m$31.6m
Operating income$10.3m$6.2m$9.5m−$2.3m$2.2m$59.8m$5.9m−$10.2m
Net income$5.2m$5.8m$8.2m−$3.5m−$9.4m$44.1m−$6.2m−$5.6m
Diluted earnings per share0.390.440.62-0.27-0.723.36-0.48-0.44
Cash from operations—−$33.0m$37.0m−$13.0m$42.0m−$16.0m$8.0m$1.0m
Total assets$404.8m$414.2m$406.2m$390.1m$381.8m$320.2m$253.7m$256.3m
Cash and short-term investments$15.4m$21.9m$55.3m$15.4m$36.6m$69.5m$97.7m$99.7m
Debt$71.6m$77.9m$64.0m$62.9m$51.3m$25.1m$26.9m$28.7m
Shareholders' equity$252.0m$242.8m$233.6m$235.4m$238.0m$216.0m$176.5m$185.3m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue17.4%6.0%62.0%
Operating income54.8%1.8%—
Net income35.5%-7.3%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin71.9%72.1%72.6%71.7%
Operating margin17.2%15.9%18.8%16.0%
Net margin5.5%6.1%10.4%11.0%

Valuation history

At each fiscal year end

FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Price to earnings0.1-1.10.70.80.30.20.28.0-0.2
Price to sales0.00.10.10.10.00.10.10.30.2

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return2%-56%-83%-46%17%-21%57%-29%-30%-10%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.